Mercia invests in fertility company
Mercia has invested an initial £400,000 in Concepta Diagnostics, which develops diagnostic devices for women’s health.
Based in York, and founded by a group of scientists who previously worked for Unipath in the fields of fertility and women’s health, Concepta has developed a range of market-ready products.
Advertisement
Hide AdAdvertisement
Hide AdIts product range recently achieved product registration in one of its largest target markets, China, where the abolition of China’s one-child policy is expected to drive significant demand for a cost effective fertility monitoring system.
Concepta’s product range provides data to women for a variety of fertility applications, using disposable test strips and devices linked to a mobile app which captures levels of key fertility hormones in urine and builds an accurate and easy-to-understand “digital diary”.
Peter Dines, investment director at Mercia, said: “The investment into Concepta reinforces the strategic rationale behind Mercia’s acquisition of EVG.”